FundingHealthcare & Life Sciences
Pandorum raises $18m Series B for exosome therapy
By Abha Lohia · Editor ·
Pandorum Technologies valuation
Pandorum Technologies was valued at $41.60M (2021), as reported by cxodigitalpulse, Inc42 and indianweb2.com on 9 February 2026.
| Valuation (2021) | $41.60M |
|---|
Pandorum Technologies: valuation and funding and every story →
Series BBengaluruFounded 2011
- Pandorum develops programmable regenerative medicine using tunable exosome-based therapies to reprogram damaged tissue
- The company raised $18 million in a Series B round led by Protons Corporate to advance its lead drug Kuragenx
- Funds will support clinical development of Kuragenx and scale global manufacturing with partners like AGC Biologics
What happened
- Pandorum Technologies has closed an $18 million Series B funding round.
- Protons Corporate led the investment in the biotech startup.
- Participants included Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family.
- The company was founded in 2011 by co-founders Tuhin Bhowmick and Arun Chandru.
- This is the latest capital raise for the Bengaluru-headquartered firm.
- The transaction involved guidance from advisor Bandana Kankani.
- The company operates in India and the United States.
- Previous funding included an $11 million Series A extension secured last year.
Why it matters
- The capital supports the clinical development of its lead program Kuragenx.
- Pandorum aims to expand into markets in the US, Japan, and the Middle East.
- The funding helps scale global manufacturing operations for its therapies.
- The move aligns with government targets for a $300 billion bioeconomy by 2030.
- Biotech ventures have grown significantly from approximately 50 to 11,000 over the past decade.
The business
- Pandorum specializes in programmable regenerative medicine and tunable exosome-based therapies.
- Its platform integrates biology, engineering, and computational methods to reprogram pathological tissue states.
- The goal is to restore functional recovery in conditions like inflammation and fibrosis.
- The lead program is Kuragenx, an ophthalmology-focused exosome therapy.
- Primary clinical focus includes ocular surface diseases such as Stevens–Johnson Syndrome and Neurotrophic Keratitis.
- Kuragenx has received US FDA Orphan Drug Designation.
- The company is expanding into inflammatory and degenerative conditions affecting lungs, liver, and the nervous system.
- Historical work included creating 3D-printed human tissues for medical research.
- Other products include bio-engineered corneal therapy and tissue models for drug testing.
- Manufacturing partnerships include AGC Biologics in Italy and Nucelion Therapeutics in Asia-Pacific.
The founders
TB
Tuhin Bhowmick
CEO- Founded in 2011.
- Leads the strategic direction of the regenerative medicine platform.
AC
Arun Chandru
Co-founder- Co-founded Pandorum Technologies in 2011.
Who put in money
- Protons Corporate lead — Led the Series B funding round for Pandorum Technologies.
- Galentic Pharma co-lead — Participated in the Series B funding round.
- Ashish Kacholia participated — Individual investor participating in the Series B round.
- Noblevast Advisory participated — Advisory firm participating in the Series B funding.
- Avinya Fund participated — Fund participating in the Series B investment.
- Burman Family participated — Family office or group participating in the Series B round.
In numbers
~$43MTotal raised to date (TheKredible) · 2026
>$32MTotal raised excluding current round · 2026
$50.59M+Total funding (Inc42 Datalabs) · 2026
46Employee count · 2026
7.53KWeb traffic (last 30 days) · 2026
$41.60MValuation · 2021
What happens next
- Pandorum plans to advance the clinical development of its lead drug Kuragenx.
- The company intends to scale global manufacturing capabilities.
- Expansion into the US, Japan, and the Middle East is planned.
- The firm is exploring partnerships in the Middle East for regional access and distribution.
Earlier rounds
- Last year · Series A extension · $11M
Words to know
- Exosome-based therapies
- Treatments using tiny vesicles released by cells to deliver therapeutic agents or repair damaged tissue.
- Orphan Drug Designation
- Regulatory status granted by the FDA to drugs treating rare diseases with small patient populations.
- Stevens–Johnson Syndrome
- A severe disorder causing skin and mucous membrane blistering and shedding, often triggered by drugs.
- Neurotrophic Keratitis
- An eye condition involving loss of corneal sensation leading to ulcers and potential vision loss.
The numbers around it
Healthcare & Life Sciences in February 2026: 18 rounds with a disclosed amount, $66.5 million in all; the biggest was Pandorum Technologies ($18M). Every sector this year →
Other articles talking about it
Terms in this story
- Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
- Series B/C: Series B, C, D and later rounds are growth rounds: large cheques for a startup with a proven model that wants to expand, enter new markets or move toward profit and a listing. In India they are usually priced in CCPS and, when foreign investors take part, must follow FEMA pricing rules.
- Lead investor: A lead investor is the investor that sets the price and main terms of a funding round, does the deepest checks on the company and usually puts in the largest cheque. When a headline says a round was led by a fund, that fund was the first to commit and shaped the deal that others joined.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
Everything on Pandorum Technologies → · All startup news on 9 February 2026 →
Is this Pandorum Technologies? Get your “Featured on StopDown” badge →